Why is Parmax Pharma falling/rising?

As of 25-Sep, Parmax Pharma Ltd's stock price is currently at Rs 33.93, reflecting an increase of Rs 1.33 or 4.08%. Today's price performance indicates that the stock has outperformed its sector by 4.94%, reaching an intraday high of Rs 33.95. However, despite this short-term gain, the stock has shown a negative trend over the past month, with a decline of 4.42%, and a significant year-to-date drop of 23.32%. The company's financial health is concerning, as it has a negative book value and weak long-term fundamental strength, evidenced by a poor EBIT to Interest ratio and declining net sales. The stock's performance is further hindered by a negative EBITDA and a substantial drop in delivery volume, which has decreased by 62.41% against the 5-day average.
In the broader market context, while Parmax Pharma's stock has risen today, it has underperformed relative to the benchmark, with a 1-week return of only 0.09% compared to the Sensex's decline of 2.23%. Over the past year, the stock has generated a return of -31.04%, contrasting sharply with the Sensex's positive performance. This underperformance in both the short and long term indicates that while there may be temporary gains, the overall outlook for Parmax Pharma remains weak, reflecting broader challenges in its financial stability and market position.